Antiretroviral Treatment

  • Moherndran ArcharyEmail author


The registration of the first antiretroviral medication (Zidovudine/AZT) by the U.S Food and Drug Administration (FDA) in 1987 marked a turning point in the management of people living with HIV. The addition of other drugs within the same class as AZT and discovery of new ART classes has resulted in the current era of combination antiretroviral treatment (ART), which changed HIV into a chronic medical condition. Expansion of global ART access has allowed 21.7 million HIV-infected people to access ART by 2017. The goal of the World Health Organisation (WHO) 90:90:90 program is to get 90% of people living with HIV to know their status, 90% of people diagnosed with HIV started on ART and 90% of those on ART to be virally suppressed. The ultimate aim is to maintain high levels of viral suppression in the population thereby decreasing the transmission risks and new HIV-infections with the aim of controlling the HIV epidemic. This chapter further describes the antiretroviral management of children with HIV.


Antiretroviral treatment Antiretroviral drugs Children Paediatrics Adolescents 


  1. 1.
    Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antivir Res. 2010;85(1):1–18. Scholar
  2. 2.
    Joint United Nations Programme on HIV/AIDS (UNAIDS). Global HIV statistics, July 2017. Available from Accessed on 23 May 2019.
  3. 3.
    Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90 An ambitious treatment target to help end the AIDS epidemic, 2014. Available from Accessed on 23 May 2019.
  4. 4.
    World Health Organisation. Update on antiretroviral regimens for treating and preventing HIV infection and update on early infant diagnosis of HIV, July 2018. Available from:
  5. 5.
    Fofana D, d’Almeida M, Lambert-Niclot S, Peytavin G, Girard P, Lafia B, Zohoun-Guidigbi L, et al. Resistance profile and treatment outcomes in HIV-infected children at virological failure in Benin, West Africa. J Antimicrob Chemother. 2018;73(11):3143–7. Scholar
  6. 6.
    Musoke P, Mudiope P, Barlow-Mosha L, Ajuna P, Bagenda D, Mubiru M, et al. Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study. BMC Pediatr. 2010;10:56. Scholar
  7. 7.
    Okomo U, Togun T, Oko F, Peterson K, Townend J, Peterson I, et al. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa. BMC Pediatr. 2012;12:95. Scholar
  8. 8.
    Penazzato M, Palladino C, Sugandhi N. Prioritizing the most needed formulations to accelerate paediatric antiretroviral therapy scale-up. Curr Opin HIV AIDS. 2017;12(4):369–76. Scholar
  9. 9.
    Leroy V, Malateste K, Rabie H, Lumbiganon P, Ayaya S, Dicko F, et al. Outcomes of antiretroviral therapy in children in Asia and Africa. J Acquir Immune Defic Syndr. 2013;62(2):208–19. Scholar
  10. 10.
    Republic of South Africa, Department of Health. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults, April 2015. Available at Accessed on 23 May 2019.
  11. 11.
    National Institutes of Health. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services, October 2018. Available from Accessed on 23 May 2019.
  12. 12.
    World Health Organisation. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV, September 2015. Available from Accessed on 23 May 2019.
  13. 13.
    Weigel R, Feldacker C, Tweya H, Gondwe C, Chiwoko J, Gumulira J, et al. Managing HIV-infected children in a low-resource, public clinic: a comparison of nurse vs. clinical officer practices in ART refill, calculation of adherence and subsequent appointments. J Int AIDS Soc. 2012;15(2):17432. Scholar
  14. 14.
    Kasirye P, Kendall L, Adkison K, Tumusiime C, Ssenyonga M, Bakeera-Kitaka S, et al. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children With HIV-1. Clin Pharmacol Ther. 2012;91(2):272–80. Scholar
  15. 15.
    Archary M, Mcllleron H, Bobat R, La Russa P, Sibaya T, Wiesner L, et al. Population pharmacokinetics of lopinavir in severely malnourished HIV infected children and the effect on treatment outcomes. Pediatr Infect Dis J. 2018;37(4):349–55. Scholar
  16. 16.
    Boerma R, Sigaloff K, Akanmu A, Inzaule S, Boele van Hensbroek M, et al. Alarming increase in pre-treatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(2):365–71. Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Paediatrics and Child HealthKing Edward VIII Hospital, Nelson R Mandela School of Medicine, UKZNDurbanSouth Africa

Personalised recommendations